+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating a new medicine called YL201 compared to the standard chemotherapy chosen by doctors in people with locally advanced or metastatic esophageal squamous cell carcinoma who have stopped responding to first-line treatment. The goal is to see if YL201 works better and is safer. The study is a large, randomized phase III trial involving multiple hospitals and also investigates how YL201 is processed in the body, immune reactions it might cause, and whether certain biological markers can predict its effects. Participants will be assigned to one of two groups one group receives YL201 alone, given as an intravenous infusion on the first day of each 3-week cycle. The other group receives a chemotherapy drug chosen by their doctor, which may be paclitaxel, docetaxel, or irinotecan, each given intravenously on specific schedules every 3 weeks. The study treatment continues as planned, with monitoring throughout the treatment period. During the study, participants will undergo regular evaluations including scans and laboratory tests to measure how well the treatments are working and to monitor side effects. The main outcome researchers will track is overall survival for up to about 36 months. They will also assess progression-free survival, response rates, duration of response, and adverse events during this time. The study will last until the end of 2028, with ongoing monitoring and data collection.

Age: 18Years +All GendersPhase 3
81 locations
E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
C

Actively Recruiting

Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.

Age: 12Years +All Genders
61 locations
C

Actively Recruiting

Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.

Age: 18Years +All Genders
38 locations
S

Actively Recruiting

Researchers are evaluating the pain relief effects and safety of three drugsoliceridine, morphine, and sufentanilin patients undergoing elective lumbar spine surgery. This randomized controlled trial aims to compare these medications when used for postoperative pain control, focusing on how well they reduce pain during movement six hours after surgery. The study also examines side effects such as nausea, vomiting, sleepiness, breathing problems, and itching within the first 48 hours after surgery. Participants are randomly assigned to one of three groups to receive intravenous patient-controlled analgesia after their surgery. The oliceridine group receives a 1.5 mg loading dose followed by a continuous infusion of 0.01 mg per kilogram per hour. The morphine group receives a 4 mg loading dose followed by an infusion of 0.03 mg per kilogram per hour. The sufentanil group receives a 4 microgram loading dose followed by an infusion of 0.03 micrograms per kilogram per hour. Each infusion is diluted in 100 ml of saline and delivered at a rate of 2 ml per hour. During the study, participants pain levels are assessed using a Visual Analogue Scale both at rest and during movement at multiple time points up to 48 hours after surgery. Researchers also monitor sedation levels, the number of times patients use the pain control button, the need for extra pain medication, and vital signs shortly after the initial dose. The study lasts through the first 48 hours after surgery, focusing on both pain relief and safety outcomes to better understand how these medications compare.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
R

Actively Recruiting

This research aims to compare whether using different sizes of tracheal catheters causes less sore throat in women after thyroid surgery. It involves female patients aged 18 to 65 years with physical health status ranging from ASA I to III, all scheduled for thyroid surgery under general anesthesia. The study focuses on evaluating sore throat incidence and severity following the procedure. Participants are randomly assigned to one of three groups, each receiving a tracheal catheter with a different inner diameter 6.0 mm, 6.5 mm, or the traditional 7.0 mm size. The study monitors how each catheter size affects postoperative sore throat at multiple time points after surgery, specifically at 1 hour, 6 hours, 24 hours, and 48 hours. During the study, researchers record the presence and severity of sore throat at these times to assess differences among the groups. The trial includes women undergoing elective thyroid surgery under general anesthesia who meet the eligibility criteria. The study is expected to run until October 2026, with participant involvement mainly around the surgery and follow-up sore throat assessments.

Age: 18Years - 65YearsFEMALE
1 location
R

Actively Recruiting

Researchers are evaluating RC1416, a bispecific homodimer nanobody, in adults with severe uncontrolled asthma to assess its effectiveness and safety. This phase II study involves 195 participants diagnosed with moderate to severe asthma, aiming to improve lung function and reduce asthma symptoms according to the 2024 GINA guidelines. Participants will be randomly assigned to receive either RC1416 or a placebo by subcutaneous injection. Two different doses of RC1416 will be tested. The study will last 32 weeks, during which participants will be monitored regularly for treatment effects and safety. Throughout the study, participants will undergo lung function tests such as pre-bronchodilator forced expiratory volume in 1 second FEV1, peak expiratory flow, and forced vital capacity measurements. They will also complete questionnaires about asthma control and quality of life. Researchers will track asthma exacerbations, medication use, and adverse events. Blood samples will be collected for pharmacokinetics, pharmacodynamics, and anti-drug antibody analysis, ensuring comprehensive safety and efficacy monitoring for up to 32 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
44 locations
E

Actively Recruiting

Researchers are evaluating whether posterosuperior bundle PSB pacing can lower the chance of atrial fibrillation AF in patients with sinus node dysfunction SND who need a permanent pacemaker. This prospective, multicenter, open-label, randomized controlled trial will enroll about 300 patients and compare PSB pacing with conventional right atrial appendage RAA pacing. The primary goal is to track AF episodes lasting 6 minutes or more over a follow-up period of up to 24 months. Participants will be randomly assigned to receive atrial pacing either at the PSB region or the RAA during pacemaker implantation. Both groups will have ventricular pacing using left bundle branch area pacing. The pacemaker will be set to DDD mode with a lower rate of 70 beats per minute during the day and 60 beats per minute at night, with rate-responsive pacing enabled and antitachycardia pacing disabled. Follow-up visits are scheduled at 3, 6, 12, and 24 months after implantation to monitor outcomes. During the study, participants will undergo device checks to detect AF episodes and other atrial high-rate events. Additional assessments include measurements of ECG and echocardiographic indices such as left ventricular ejection fraction and atrial diameters, laboratory tests including NT-pro BNP and eGFR, and monitoring for mortality and safety events. The primary outcome is the incidence of AF episodes lasting 6 minutes or longer. Secondary outcomes and safety endpoints will also be evaluated throughout the 24-month follow-up period.

Age: 18Years +All GendersPhase Not Applicable
10 locations

1-10 of 14

1